Misplaced Pages

Odapipam

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Abandoned D1 receptor antagonist Pharmaceutical compound
Odapipam
Clinical data
Other namesNNC 01-0756; NNC-01-0756; NNC-010756; NNC010756; NNC01-0756; NNC-756; NNC756; NNC 0756; NNC0756; NO-756; NO756
Drug classDopamine D1 receptor antagonist
Identifiers
IUPAC name
  • (5S)-8-chloro-5-(2,3-dihydro-1-benzofuran-7-yl)-3-methyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H20ClNO2
Molar mass329.82 g·mol
3D model (JSmol)
SMILES
  • CN1CCC2=CC(=C(C=C2(C1)C3=CC=CC4=C3OCC4)O)Cl
InChI
  • InChI=1S/C19H20ClNO2/c1-21-7-5-13-9-17(20)18(22)10-15(13)16(11-21)14-4-2-3-12-6-8-23-19(12)14/h2-4,9-10,16,22H,5-8,11H2,1H3/t16-/m1/s1
  • Key:SKMVRXPBCSTNKE-MRXNPFEDSA-N

Odapipam (INNTooltip International Nonproprietary Name; developmental code names NNC 01-0756, NNC-756, NO-756) is a selective D1 receptor antagonist of the benzazepine group which was investigated as a potential antipsychotic but was never marketed.

It has more than 5,000-fold selectivity for the dopamine D1 receptor (Ki = 0.17 nM) over the dopamine D2 receptor (Ki = 942 nM). Its affinities for other dopamine receptors, such as the dopamine D5 receptor, were not reported. In addition to the dopamine D1 receptor, odapipam showed relatively high affinity for the serotonin 5-HT2 receptor (Ki = 4.5 nM; 26-fold lower than for the D1 receptor).

The drug was first described in the scientific literature by 1988.

See also

References

  1. Shen WW (1999). "A history of antipsychotic drug development". Compr Psychiatry. 40 (6): 407–414. doi:10.1016/s0010-440x(99)90082-2. PMID 10579370.
  2. Seamans JK, Yang CR (September 2004). "The principal features and mechanisms of dopamine modulation in the prefrontal cortex". Prog Neurobiol. 74 (1): 1–58. doi:10.1016/j.pneurobio.2004.05.006. PMID 15381316.
  3. ^ Neumann J, Hofmann B, Dhein S, Gergs U (March 2023). "Role of Dopamine in the Heart in Health and Disease". Int J Mol Sci. 24 (5): 5042. doi:10.3390/ijms24055042. PMC 10003060. PMID 36902474.
  4. ^ Andersen PH, Grønvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C, Nielsen EB (August 1992). "NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists". Eur J Pharmacol. 219 (1): 45–52. doi:10.1016/0014-2999(92)90578-r. PMID 1397049.
  5. Waddington JL (January 1989). "Functional interactions between D-1 and D-2 dopamine receptor systems: their role in the regulation of psychomotor behaviour, putative mechanisms, and clinical relevance". J Psychopharmacol. 3 (2): 54–63. doi:10.1177/026988118900300202. PMID 22156499.
Dopamine receptor modulators
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
Serotonin receptor modulators
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT3–7
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7


Stub icon

This psychoactive drug-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: